GVOKE KIT Drug Patent Profile

Which patents cover Gvoke Kit, and what generic alternatives are available?

Gvoke Kit is a drug marketed by Xeris and is included in one NDA. There is one patent protecting this drug.

This drug has twenty-two patent family members in fifteen countries.

The generic ingredient in GVOKE KIT is glucagon. There are twelve drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the glucagon profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Gvoke Kit

A generic version of GVOKE KIT was approved as glucagon by FRESENIUS KABI USA on May 8^th, 2015.

Summary for GVOKE KIT

International Patents:	22
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for GVOKE KIT
What excipients (inactive ingredients) are in GVOKE KIT?	GVOKE KIT excipients list
DailyMed Link:	GVOKE KIT at DailyMed

See drug prices for GVOKE KIT

Pharmacology for GVOKE KIT

Drug Class	Antihypoglycemic Agent Gastrointestinal Motility Inhibitor
Physiological Effect	Decreased GI Motility Decreased GI Smooth Muscle Tone Decreased Glycolysis Increased Gluconeogenesis Increased Glycogenolysis

Anatomical Therapeutic Chemical (ATC) Classes for GVOKE KIT

H04AA	Glycogenolytic hormones
H04A	GLYCOGENOLYTIC HORMONES
H04	PANCREATIC HORMONES
H	Systemic hormonal preparations, excluding sex hormones and insulins

US Patents and Regulatory Information for GVOKE KIT

GVOKE KIT is protected by one US patents.

Patents protecting GVOKE KIT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Xeris	GVOKE KIT	glucagon	SOLUTION;SUBCUTANEOUS	212097-005	Aug 20, 2021		RX	Yes	Yes			Y

EU/EMA Drug Approvals for GVOKE KIT

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Tetris Pharma B.V	Ogluo	glucagon	EMEA/H/C/005391 Ogluo is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.	Authorised	no	no	no	2021-02-11
Eli Lilly Nederland B.V.	Baqsimi	glucagon	EMEA/H/C/003848 Baqsimi is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 4 years and over with diabetes mellitus.	Authorised	no	no	no	2019-12-16

International Patents for GVOKE KIT

See the table below for patents covering GVOKE KIT around the world.

Country	Patent Number	Title	Estimated Expiration
South Korea	20180054847	양극성 용매에서 안정한 치료 제형들의 제조방법.
Canada	3204984	METHODES DE PRODUCTION DE FORMULATIONS THERAPEUTIQUES STABLES DANS DES SOLVANTS POLAIRES APROTIQUES (METHODS FOR PRODUCING STABLE THERAPEUTIC FORMULATIONS IN APROTIC POLAR SOLVENTS)
Israel	258298	שיטות לייצור תכשירי גלוקגון יציבים בסולבנטים פולרים אפרוטים (Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents)
China	115531523	在非质子极性溶剂中制备稳定的普兰林肽治疗制剂的方法 (Method for preparing stable pramlintide therapeutic formulations in aprotic polar solvents)